193 related articles for article (PubMed ID: 34509306)
1. Efficacy of the pretreatment geriatric nutritional risk index for predicting severe adverse events in patients with head and neck cancer treated with chemoradiotherapy.
Nakayama M; Ohnishi K; Adachi M; Ii R; Matsumoto S; Nakamura M; Miyamoto H; Hirose Y; Nishimura B; Tanaka S; Wada T; Tabuchi K
Auris Nasus Larynx; 2022 Apr; 49(2):279-285. PubMed ID: 34509306
[TBL] [Abstract][Full Text] [Related]
2. The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin.
Fujiwara Y; Sato Y; Hayashi N; Fukuda N; Wang X; Nakano K; Ohmoto A; Urasaki T; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takahashi S
J Geriatr Oncol; 2023 Jun; 14(5):101523. PubMed ID: 37229881
[TBL] [Abstract][Full Text] [Related]
3. The Geriatric Nutritional Risk Index as a Prognostic Factor in Patients with Advanced Head and Neck Cancer.
Nakayama M; Gosho M; Adachi M; Ii R; Matsumoto S; Miyamoto H; Hirose Y; Nishimura B; Tanaka S; Wada T; Tabuchi K
Laryngoscope; 2021 Jan; 131(1):E151-E156. PubMed ID: 32083731
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the MNA-SF, MUST, and NRS-2002 nutritional tools in predicting treatment incompletion of concurrent chemoradiotherapy in patients with head and neck cancer.
Hsueh SW; Lai CC; Hung CY; Lin YC; Lu CH; Yeh KY; Tsang NM; Hung YS; Chang PH; Chou WC
Support Care Cancer; 2021 Sep; 29(9):5455-5462. PubMed ID: 33704566
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Fukuda N; Yunokawa M; Fujiwara Y; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1322. PubMed ID: 33295110
[TBL] [Abstract][Full Text] [Related]
6. Objective evaluation of nutritional status using the prognostic nutritional index during and after chemoradiotherapy in Japanese patients with head and neck cancer: a retrospective study.
Fujiwara D; Tsubaki M; Takeda T; Miura M; Nishida S; Sakaguchi K
Eur J Hosp Pharm; 2021 Sep; 28(5):266-270. PubMed ID: 34426479
[TBL] [Abstract][Full Text] [Related]
7. A prospective nutritional assessment using Mini Nutritional Assessment-short form among patients with head and neck cancer receiving concurrent chemoradiotherapy.
Hung CY; Hsueh SW; Lu CH; Chang PH; Chen PT; Yeh KY; Wang HM; Tsang NM; Huang PW; Hung YS; Chen SC; Chou WC
Support Care Cancer; 2021 Mar; 29(3):1509-1518. PubMed ID: 32710174
[TBL] [Abstract][Full Text] [Related]
8. The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.
Haas M; Lein A; Fuereder T; Brkic FF; Schnoell J; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839241
[TBL] [Abstract][Full Text] [Related]
9. Geriatric Nutritional Risk Index as a prognostic factor in patients with esophageal squamous cell carcinoma -retrospective cohort study.
Yamana I; Takeno S; Shimaoka H; Yamashita K; Yamada T; Shiwaku H; Hashimoto T; Yamashita Y; Hasegawa S
Int J Surg; 2018 Aug; 56():44-48. PubMed ID: 29602015
[TBL] [Abstract][Full Text] [Related]
10. Pre-therapeutic nutritional assessment for predicting severe adverse events in patients with head and neck cancer treated by radiotherapy.
Kono T; Sakamoto K; Shinden S; Ogawa K
Clin Nutr; 2017 Dec; 36(6):1681-1685. PubMed ID: 27847115
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the Geriatric Nutritional Risk Index for Predicting Overall Survival in Patients with Head and Neck Cancer: A Meta-Analysis.
Yiu CY; Liu CC; Wu JY; Tsai WW; Liu PH; Cheng WJ; Chen JY; Hung KC
Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892423
[TBL] [Abstract][Full Text] [Related]
12. [Nutritional surveillance in head and neck cancer patients during radiotherapy--the difference between concurrent chemoradiotherapy using high-dose cisplatin and radiotherapy alone].
Nakahara S; Yoshino K; Fujii T; Uemura H; Suzuki M; Nishiyama K; Inohara H
Nihon Jibiinkoka Gakkai Kaiho; 2012 Oct; 115(10):902-9. PubMed ID: 23214048
[TBL] [Abstract][Full Text] [Related]
13. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck.
Kimura H; Hamauchi S; Kawai S; Onozawa Y; Yasui H; Yamashita A; Ogawa H; Onoe T; Kamijo T; Iida Y; Onitsuka T; Yokota T
Int J Clin Oncol; 2020 Feb; 25(2):258-266. PubMed ID: 31620932
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Vulnerability Assessment in Patients with Primary Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiation Therapy.
Chou WC; Chang PH; Chen PT; Wang HM; Yeh KY; Lu CH; Hung YS; Tung-Chieh Chang J; Tsang NM; Ho YW; Chen SY; Lee SH; Hung CY; Wang LJ; Liao KC; Lin CH; Tang WR; Lin YC
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):602-611. PubMed ID: 31987971
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of Albumin and Neutrophil-to-Lymphocyte Ratio Score for Treatment Completeness and Safety Profiles in Patients With Head and Neck Cancer Receiving Definitive Concurrent Chemoradiotherapy.
Hsu CC; Chou WC; Hung YS; Lin SY; Hung CY; Yeh KY; Wang HM; Lu CH
In Vivo; 2022; 36(6):2875-2883. PubMed ID: 36309354
[TBL] [Abstract][Full Text] [Related]
17. Does the geriatric nutrition risk index predict the prognosis of patients with oral squamous cell carcinoma?
Yamagata K; Fukuzawa S; Uchida F; Terada K; Ishibashi-Kanno N; Bukawa H
Br J Oral Maxillofac Surg; 2022 May; 60(4):475-481. PubMed ID: 35086741
[TBL] [Abstract][Full Text] [Related]
18. Effect of prophylactic tube feeding in head and neck cancer patients with high Mallampati score undergoing definitive concurrent chemoradiotherapy.
Lu CH; Hsu CC; Su PH; Lin SY; Yeh KY; Hsueh SW; Chang JT; Wang HM; Hung YS; Chou WC
Support Care Cancer; 2023 Jun; 31(7):384. PubMed ID: 37289404
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
20. Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy.
Shodo R; Yamazaki K; Ueki Y; Takahashi T; Horii A
Eur Arch Otorhinolaryngol; 2021 Jun; 278(6):2001-2009. PubMed ID: 32772234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
